-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] With the aging of the population, the upgrading of consumption, and the continuous blessing of national policy dividends, in recent years, the Chinese medicine industry has begun to enter a period of development opportunities, and the market prospects are also becoming more and more broad
.
The industry predicts that the market size of traditional Chinese medicine will exceed one trillion yuan by 2022 and reach 1,137.
5 billion yuan in 2024
.
It is worth noting that the huge market not only makes companies on the track full of confidence in their future development, but also attracts more companies to deploy
.
The innovative research and development of traditional Chinese medicine has been highly praised by enterprises, and pharmaceutical machine enterprises have ushered in opportunities (Source: Pharmaceutical Network) Pharmaceutical companies are accelerating the layout of the traditional Chinese medicine industry It is reported that many pharmaceutical companies have recently planned to increase the layout of the traditional Chinese medicine industry through mergers and acquisitions
.
For example, on August 9, Dorui Medicine announced that the company plans to acquire a 40% stake in Bozhou Tianji held by Hubei Tianji
.
For the purpose of this acquisition, the company stated that it is conducive to accelerating the improvement of the company's traditional Chinese medicine industry layout and further enhancing the company's profitability
.
On July 25, Wanbangde also announced that it intends to acquire a total of 238 million shares of Hong Kong-listed company Kangchen Pharmaceutical by paying cash, accounting for 29.
50% of its total share capital
.
On July 18, Weikang Pharmaceutical signed the "Share Subscription Agreement" with Hangzhou Haishan Equipment Co.
, Ltd.
and related parties, and planned to increase the capital of Hangzhou Haishan by 20 million yuan at the price of 1.
51 yuan per share in cash.
acquire it
.
It is worth mentioning that, according to public information, Hangzhou Haishan is an enterprise focusing on the research and development, production and sales of traditional Chinese medicine processing equipment
.
Has a stable R&D team and an expanding customer base and market
.
From the above point of view, a large number of pharmaceutical companies are expanding the Chinese medicine industry more quickly through mergers and acquisitions.
However, returning to the long-term development of enterprises, the industry believes that Chinese medicine companies still need to focus on innovation and research and development in order to go further
.
In fact, under the frequent blowing of policies in recent years, the innovative research and development of traditional Chinese medicine is being touted by enterprises
.
At present, the results have gradually begun to show
.
According to the "2021 Annual Drug Evaluation Report" released by the State Food and Drug Administration on June 1, there are 54 innovative traditional Chinese medicines in the registration application of innovative drugs, an increase of 134.
78% year-on-year, and the growth rate exceeds that of innovative chemical drugs and innovative drugs.
biological products
.
In addition, as of April this year, 8 new TCM Class 1 drugs have been launched, and more than 60 new TCM Class 1 drugs have been in the stages of clinical application, clinical approval, and application for marketing
.
With the popularity of innovative research and development of traditional Chinese medicine, there is a huge market space and promising prospects for pharmaceutical machine companies to help traditional Chinese medicine innovation.
After the profit of the enterprise is reduced, how to control the cost,
etc.
In this regard, the industry believes that traditional Chinese medicine enterprises can improve production efficiency through automated, intelligent, and information-based traditional Chinese medicine production and testing equipment, reduce labor input, and ensure that the quality of traditional Chinese medicine products is more stable and controllable
.
However, it should be noted that compared with chemical drugs and biological drugs, the research and development and production of new traditional Chinese medicines are more difficult, and their material basis and pharmacological mechanism are more complex.
Research on their safety and effectiveness also requires new method new technology
.
For pharmaceutical machine companies, while ushering in opportunities, they will also face challenges
.
It is understood that in order to better meet the production needs of traditional Chinese medicine enterprises, a large number of pharmaceutical machine companies have already begun to actively respond by innovating and upgrading pharmaceutical equipment
.
For example, a certain enterprise has been continuously improving and innovating around traditional Chinese medicine pills and suppositories equipment for decades, developing from a single product to a complete set of equipment, from a single equipment to providing a complete set of technical solutions
.
At present, the company has formed "automatic Chinese medicine pill linkage production line, Chinese medicine big honey pill wax shell packaging unit, suppository filling production line, high-speed automatic bottling and packaging production line, automatic feeding and discharging pill (tablet) polishing and coating unit, tunnel type multi- More than 100 products in 7 series, including microwave drying and sterilizing machine
.
It has also successively undertaken complete sets of equipment projects for national key pill production enterprises such as Beijing Tongrentang, Henan Wanxi Pharmaceutical, Changsha Jiuzhitang, Lanzhou Foci, Shanxi Guangyuyuan, Guangzhou Chenliji, etc.
, providing professional pharmaceutical equipment guarantee for the development of these enterprises
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
The industry predicts that the market size of traditional Chinese medicine will exceed one trillion yuan by 2022 and reach 1,137.
5 billion yuan in 2024
.
It is worth noting that the huge market not only makes companies on the track full of confidence in their future development, but also attracts more companies to deploy
.
The innovative research and development of traditional Chinese medicine has been highly praised by enterprises, and pharmaceutical machine enterprises have ushered in opportunities (Source: Pharmaceutical Network) Pharmaceutical companies are accelerating the layout of the traditional Chinese medicine industry It is reported that many pharmaceutical companies have recently planned to increase the layout of the traditional Chinese medicine industry through mergers and acquisitions
.
For example, on August 9, Dorui Medicine announced that the company plans to acquire a 40% stake in Bozhou Tianji held by Hubei Tianji
.
For the purpose of this acquisition, the company stated that it is conducive to accelerating the improvement of the company's traditional Chinese medicine industry layout and further enhancing the company's profitability
.
On July 25, Wanbangde also announced that it intends to acquire a total of 238 million shares of Hong Kong-listed company Kangchen Pharmaceutical by paying cash, accounting for 29.
50% of its total share capital
.
On July 18, Weikang Pharmaceutical signed the "Share Subscription Agreement" with Hangzhou Haishan Equipment Co.
, Ltd.
and related parties, and planned to increase the capital of Hangzhou Haishan by 20 million yuan at the price of 1.
51 yuan per share in cash.
acquire it
.
It is worth mentioning that, according to public information, Hangzhou Haishan is an enterprise focusing on the research and development, production and sales of traditional Chinese medicine processing equipment
.
Has a stable R&D team and an expanding customer base and market
.
From the above point of view, a large number of pharmaceutical companies are expanding the Chinese medicine industry more quickly through mergers and acquisitions.
However, returning to the long-term development of enterprises, the industry believes that Chinese medicine companies still need to focus on innovation and research and development in order to go further
.
In fact, under the frequent blowing of policies in recent years, the innovative research and development of traditional Chinese medicine is being touted by enterprises
.
At present, the results have gradually begun to show
.
According to the "2021 Annual Drug Evaluation Report" released by the State Food and Drug Administration on June 1, there are 54 innovative traditional Chinese medicines in the registration application of innovative drugs, an increase of 134.
78% year-on-year, and the growth rate exceeds that of innovative chemical drugs and innovative drugs.
biological products
.
In addition, as of April this year, 8 new TCM Class 1 drugs have been launched, and more than 60 new TCM Class 1 drugs have been in the stages of clinical application, clinical approval, and application for marketing
.
With the popularity of innovative research and development of traditional Chinese medicine, there is a huge market space and promising prospects for pharmaceutical machine companies to help traditional Chinese medicine innovation.
After the profit of the enterprise is reduced, how to control the cost,
etc.
In this regard, the industry believes that traditional Chinese medicine enterprises can improve production efficiency through automated, intelligent, and information-based traditional Chinese medicine production and testing equipment, reduce labor input, and ensure that the quality of traditional Chinese medicine products is more stable and controllable
.
However, it should be noted that compared with chemical drugs and biological drugs, the research and development and production of new traditional Chinese medicines are more difficult, and their material basis and pharmacological mechanism are more complex.
Research on their safety and effectiveness also requires new method new technology
.
For pharmaceutical machine companies, while ushering in opportunities, they will also face challenges
.
It is understood that in order to better meet the production needs of traditional Chinese medicine enterprises, a large number of pharmaceutical machine companies have already begun to actively respond by innovating and upgrading pharmaceutical equipment
.
For example, a certain enterprise has been continuously improving and innovating around traditional Chinese medicine pills and suppositories equipment for decades, developing from a single product to a complete set of equipment, from a single equipment to providing a complete set of technical solutions
.
At present, the company has formed "automatic Chinese medicine pill linkage production line, Chinese medicine big honey pill wax shell packaging unit, suppository filling production line, high-speed automatic bottling and packaging production line, automatic feeding and discharging pill (tablet) polishing and coating unit, tunnel type multi- More than 100 products in 7 series, including microwave drying and sterilizing machine
.
It has also successively undertaken complete sets of equipment projects for national key pill production enterprises such as Beijing Tongrentang, Henan Wanxi Pharmaceutical, Changsha Jiuzhitang, Lanzhou Foci, Shanxi Guangyuyuan, Guangzhou Chenliji, etc.
, providing professional pharmaceutical equipment guarantee for the development of these enterprises
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
